Stockreport

Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Karyopharm Therapeutics Inc.  (KPTI) 
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.karyopharm.com/investor-relations
PDF SHANGHAI and PHILADELPHIA, April 14, 2020 /PRNewswire/ -- Antengene announced today that it has dosed the first patient in Taiwan, China in its phase 1 open-label clinic [Read more]